Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.19
Change: 0.035 (1.66%)
Spread: 0.09 (4.286%)
Open: 2.06
High: 2.15
Low: 2.06
Prev. Close: 2.11
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks looking for direction before US inflation

Wed, 12th Apr 2023 08:49

(Alliance News) - Stock prices in London opened mixed on Wednesday, as caution prevailed ahead of a US inflation reading and minutes from the Federal Reserve's March meeting.

The FTSE 100 index opened up 20.87 points, 0.3%, at 7,806.59. The FTSE 250 was down 33.76 points, 0.2%, at 18,922.29, and the AIM All-Share was down 0.62 of a point at 816.23.

The Cboe UK 100 was 0.3% higher at 780.92, the Cboe UK 250 down 0.3% at 16,482.70, and the Cboe Small Companies was down 0.6% at 13,189.85.

In European equities, the CAC 40 in Paris and the DAX 40 in Frankfurt both were up 0.2%.

"A dose of caution has been injected into financial markets as investors brace for the latest reading on US inflation," said Hargreaves Lansdown analyst Susannah Streeter.

US inflation data for March will be released at 1330 BST. Markets are expecting the annual inflation rate to cool to 5.2% from 6.0%, according to FXStreet. From the previous month, consumer prices are expected to rise 0.4%, compared to 0.5% in February.

Core inflation - excluding food and energy - is expected to edge up to 5.6% annually from 5.5% in February.

"The worry is that core inflation...may be proving harder to bring down more quickly, which could harden [Federal Reserve] policymakers' resolve," HL's Streeter noted.

"Another 0.25% hike is already expected in May, and a stronger than expected core inflation reading, could tip the balance in forecasts towards yet another rate rise in June, which may set off a fresh round of equity selling, particularly for companies in the sensitive tech sector," she added.

There also will be the release of the Federal Open Market Committee meeting minutes at 1900 BST.

At its March meeting, the Fed lifted interest rates by 25 basis points to a 475-500 basis point target range, resisting the urge to pause hikes in the face of banking sector turmoil.

"There is likely to be reference to the recent banking turmoil, although comments from one Fed member have already suggested that there are no signs yet of business or consumer spending being influenced by tighter lending conditions," said interactive investor analyst Richard Hunter.

In the US on Tuesday, Wall Street had a muted session, with the Dow Jones Industrial Average ending up 0.3%, the S&P 500 flat, and the Nasdaq Composite down 0.4%.

The dollar was mixed against major currencies in early exchanges.

Sterling was quoted at USD1.2432 early Wednesday, higher than USD1.2427 at the London equities close on Tuesday. The euro traded at USD1.0931, up from USD1.0914. Against the yen, the dollar was quoted at JPY133.64, up slightly versus JPY133.61.

In Asia on Wednesday, the Nikkei 225 index closed up 0.6%. In China, the Shanghai Composite added 0.4%, though the Hang Seng index in Hong Kong was down 1.0%. The S&P/ASX 200 in Sydney closed up 0.5%.

In London's FTSE 100 index, student accommodation provider Unite added 0.7%, updating on its UK Student Accommodation Fund and London Student Accommodation joint venture's quarterly trading.

In the 2023/24 academic year, it noted "strong progress" in booking, with 90% of rooms already sold.

"Reservations are significantly ahead of recent sales cycles, reflecting strong demand from both new and existing students as well as new nomination agreements with universities," said Chief Executive Richard Smith.

The progress reinforces its confidence in rental growth of 6% to 7% for the academic year, Unite said.

Anglo American fell 1.6%.

The miner announced the value of rough diamond sales for De Beers in the third sales cycle of the year. Sales values rose to USD540 million from USD497 million in the second cycle. However, sales were down from USD566 million in the third cycle of 2022. The third cycle ran from March 27 to April 11.

"Sales were in line with expectations and we continue to see some encouraging positive trends in consumer demand for diamond jewellery, not least in China where we're beginning to see some signs of recovery in consumer confidence following the relaxation of travel restrictions," said De Beers CEO Al Cook.

Gold was quoted at USD2,016.14 an ounce early Wednesday, higher than USD2,002.83 on Tuesday.

In the FTSE 250, Tullow Oil dropped 4.0%, as Jefferies cut the stock to 'underperform' from 'hold'.

Brent oil fetched USD85.80 a barrel, higher than USD85.22.

Elsewhere, Hikma Pharmaceuticals fell 0.5% as it named Riad Mishlawi as its new chief executive officer.

Mishlawi will become CEO from September 1, and is currently the president of Hikma's Injectables business. Acting CEO Said Darwazah will step down, and resume his role as executive chair.

Among London's small-caps, De La Rue plunged 29%.

The banknote printer said it has been hurt by demand for banknotes sinking to a more than 20-year low. It expects full year adjusted operating profit for the year ended March 25 to be "a mid-single digit percentage below market expectations".

De La Rue said it is seeing signs of recovery, with a "significant number of new tenders actively underway", though the pace of a bounce back is uncertain.

De La Rue added: "The company is in discussions with its lending banks in relation to seeking an amendment to its banking covenants, reflecting the revised outlook and also reflecting the increase in the company's funding costs resulting from higher Bank of England base rates."

More positively, it expects revenue in its Authentication to top GBP100 million for the first time in the new financial year.

On AIM, ImmuPharma jumped 10%.

The specialist drug discovery and development company said it had received confirmation of a meeting with the US Food & Drug Administration. The pre-investigational new drug meeting will take place on May 16. It concerns the phase 2/3 adaptive trial study protocol for P140 in chronic idiopathic demyelinating polyneuropathy.

"We are delighted to be moving P140 into its second indication for CIDP patients who suffer from a rare disease with high unmet medical need. This is a great example of P140's broad potential," said CEO Tim McCarthy.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Oct 2014 11:19

UK MIDDAY BRIEFING: GKN A Winner As Earnings Season Hits Full Swing

Read more
21 Oct 2014 11:16

Immupharma raises £3.4m as it gears up for Lupuzor Phase III trial

Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus. The new shares were issued, principally from long-time investor Aviva, at a price of 53p per

Read more
21 Oct 2014 11:00

UK WINNERS & LOSERS: ASOS Back In Style Despite Profit Fall

Read more
20 Oct 2014 06:59

ImmuPharma Gets EUR400,000 Grant In France For Urelix Technology

Read more
5 Oct 2014 13:32

Sunday share tips: BG Group, Genel Energy, Palace Capital

Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. I

Read more
30 Sep 2014 09:27

ImmuPharma Poised For Phase III Trials Of Lupuzor As Loss As Expected

Read more
27 Jun 2014 12:10

ImmuPharma Forms European Research Team As Part Of Peptides Drive

Read more
16 Jun 2014 10:52

ImmuPharma Granted New US Patent For Nucant Cancer Treatments

LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-relate

Read more
16 Jun 2014 08:14

Immupharma gains new patents for Nucant treatments

Drug developer Immupharma has improved the patent protection of its Nucant cancer treatments. Immupharma said the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of its Nucant family. A similar grant has been obtained from the European Union, Japane

Read more
21 May 2014 13:14

ImmuPharma's patient approach disappoints

Losses from AIM-listed biotech ImmuPharma were less than expected, with the company working hard to commercialise its Lupuzor lupus treatment via phase III clinical trials and new potential partners. Lupuzor has received approval from the US Food and Drug Administration (FDA) to start late-stage t

Read more
21 May 2014 11:45

ImmuPharma Losses Widen As It Accelerates Research And Development

LONDON (Alliance News) - Specialist drug discovery and development company ImmuPharma PLC Wednesday said it losses widened in 2013, as its invests in developing its lupus and cancer treatments. The company posted pretax profit loss of GBP4.4 million for 2013, compared with a GBP4.2 million

Read more
27 Sep 2013 12:23

ImmuPharma Narrows Losses, Developing Lupus Treatment

Read more
27 Sep 2013 10:30

ImmuPharma reports half-year loss

ImmuPharma's shares fell in Friday morning trading as the company reported a half-year loss in line with last year. Losses for the first six months of the year remained unchanged at £1.8m and loss per share held steady at 2.17p. The drug discovery and development company said during the period it

Read more
13 Aug 2013 09:17

Immupharma progresses with cancer treatment trials

ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients. IPP-204106 is 10 times more efficient that the previous Nucant version in p

Read more
28 Jan 2013 16:06

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.